Equities analysts expect Protagonist Therapeutics Inc (NASDAQ:PTGX) to announce earnings of ($0.30) per share for the current quarter, Zacks reports. Two analysts have provided estimates for Protagonist Therapeutics’ earnings. The highest EPS estimate is ($0.09) and the lowest is ($0.51). Protagonist Therapeutics posted earnings of ($0.89) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 66.3%. The business is scheduled to announce its next quarterly earnings report on Tuesday, August 14th.
On average, analysts expect that Protagonist Therapeutics will report full-year earnings of ($0.98) per share for the current fiscal year, with EPS estimates ranging from ($1.23) to ($0.73). For the next fiscal year, analysts forecast that the business will report earnings of ($1.77) per share, with EPS estimates ranging from ($2.24) to ($1.29). Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that cover Protagonist Therapeutics.
Protagonist Therapeutics (NASDAQ:PTGX) last issued its quarterly earnings data on Wednesday, May 9th. The company reported ($0.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.07). The business had revenue of $10.78 million during the quarter, compared to analysts’ expectations of $10.70 million.
In other news, major shareholder X L.P. Canaan sold 77,591 shares of Protagonist Therapeutics stock in a transaction that occurred on Monday, May 14th. The stock was sold at an average price of $6.37, for a total value of $494,254.67. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Bryan Giraudo bought 10,000 shares of the firm’s stock in a transaction dated Wednesday, May 16th. The stock was purchased at an average price of $6.46 per share, with a total value of $64,600.00. Following the transaction, the director now owns 10,000 shares in the company, valued at approximately $64,600. The disclosure for this purchase can be found here. In the last quarter, insiders sold 281,856 shares of company stock valued at $2,366,396. Insiders own 13.80% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of PTGX. Bank of Montreal Can boosted its position in Protagonist Therapeutics by 1,086.0% during the 4th quarter. Bank of Montreal Can now owns 5,930 shares of the company’s stock valued at $123,000 after purchasing an additional 5,430 shares during the period. Cubist Systematic Strategies LLC boosted its position in Protagonist Therapeutics by 255.0% during the 1st quarter. Cubist Systematic Strategies LLC now owns 11,593 shares of the company’s stock valued at $100,000 after purchasing an additional 8,327 shares during the period. Prudential Financial Inc. acquired a new position in Protagonist Therapeutics during the 1st quarter valued at approximately $116,000. Two Sigma Advisers LP acquired a new position in Protagonist Therapeutics during the 4th quarter valued at approximately $362,000. Finally, Schwab Charles Investment Management Inc. boosted its position in Protagonist Therapeutics by 46.2% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 19,300 shares of the company’s stock valued at $402,000 after purchasing an additional 6,100 shares during the period. Institutional investors own 56.28% of the company’s stock.
Protagonist Therapeutics traded up $0.12, reaching $7.46, during mid-day trading on Friday, according to MarketBeat. 1,441 shares of the company’s stock traded hands, compared to its average volume of 245,279. Protagonist Therapeutics has a 1-year low of $5.50 and a 1-year high of $23.97. The firm has a market cap of $153.73 million, a PE ratio of -3.51 and a beta of 3.28.
About Protagonist Therapeutics
Protagonist Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based drugs to address various unmet medical needs. The company's lead product candidates include PTG-100, an oral alpha-4-beta-7 integrin- antagonist that is in Phase II b clinical trial for the treatment of ulcerative colitis, as well as for treating chronic pouchitis, a gastrointestinal (GI) condition that occurs in post-surgical inflammatory bowel disease (IBD) patients; PTG-200, an oral interleukin-23 receptor antagonist, which is in Phase I clinical trial for the treatment of IBD; and PTG-300, an injectable hepcidin mimetic, which has completed Phase I study for use in the treatment of beta-thalassemia, as well as for treating other diseases, such as hereditary hemochromatosis, polycythemia vera, siderophilic infections, and liver fibrosis.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.